# OnCo record arovella-therapeutics (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/arovella-therapeutics/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "arovella-therapeutics" ;
  schema:name "Arovella Therapeutics"@en ;
  schema:description "Arovella Therapeutics makes ready-made cell therapies from donor immune cells called iNKT cells, engineered to find cancer cells. Its first product, ALA-101, is in an early trial in people with lymphoma or leukaemia that carry the marker CD19."@en ;
  schema:url <https://onco.cc/companies/arovella-therapeutics/>, <https://www.arovella.com/> ;
  schema:dateModified "2026-10-29"^^xsd:date ;
  schema:citation <https://www.arovella.com/>, <https://www.arovella.com/ala-101-car19-inkt>, <https://clinicaltrials.gov/study/NCT07518329> ;
  schema:addressCountry "AU" ;
  onco:cancers <https://onco.cc/cancers/non-hodgkin-lymphoma/>, <https://onco.cc/cancers/leukaemia/> ;
  onco:sections <https://onco.cc/fronts/cell-therapy/>, <https://onco.cc/fronts/immunotherapy/> ;
  onco:technologies <https://onco.cc/technologies/car-t/>, <https://onco.cc/technologies/allogeneic-cell-therapy/> ;
  onco:targets <https://onco.cc/targets/cd19/>, <https://onco.cc/targets/cldn18-2/> .